Full video transcriptClick to expand
Auto-generated transcript of @drjonesdc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00No more weekly shots of your GLP once?
- 0:03That's some craziness.
- 0:04Early data shows 14%, bio-glutide, the newest GLP one.
- 0:09It is four receptors.
- 0:11That's pretty crazy, Tom.
- 0:12You on my channel?
- 0:13Hi, I'm Dr. Jones, DC, a weight loss expert,
- 0:15and a coach, thousands of patients on GLP once,
- 0:18team with my provider.
- 0:19So first came O'Zambic, one receptor,
- 0:21then Monjaro two, right at true tide three,
- 0:24and everybody thought that was the future, freaking crazy.
- 0:27But now we got the big quad, all four, bio-glutide,
- 0:30GLP one, like O'Zambic, GIP, like Monjaro,
- 0:33glucagon like red at true tide,
- 0:35and then bio-glutide has its own new aspect, the IGF one.
- 0:39That fourth one really hits it on the muscle mass,
- 0:4213.8% weight loss, and most of it coming from fat.
- 0:46And it's an epil, so you don't have to worry
- 0:47about dealing with the hassle of injections.
- 0:49No refrigeration, just a daily tablet.
- 0:52Red at true tide still needs weekly shots,
- 0:54but this does not.
- 0:55But with our still in trials, I just wanna be clear,
- 0:57but only one of them is gonna let you
- 0:58skip your needles forever.
- 0:59What future do you want and drop it in the comments,
- 1:02cause I do check these out every day.
- 1:03And I wanna know, bigger picture,
- 1:05what is your guys' long-term plan?
- 1:07Let me know, and we'll see you guys later.
Bioglutide's 14% weight loss claim: what the data actually shows
Quick answer
Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.8% weight reduction in early-stage trial data and an oral tablet formulation currently under clinical investigation. As of mid-2025, no peer-reviewed Phase 2 or Phase 3 data for bioglutide has been published in a major medical journal, meaning all efficacy figures circulating online derive from preliminary or company-disclosed sources. Patients considering GLP-1 class therapies should be evaluated and managed by a licensed medical prescriber using drugs with established FDA approval status.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Bioglutide's 14% weight loss claim: what the data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Bioglutide's 14% weight loss claim: what the data actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Bioglutide's 14% weight loss claim: what the data actually shows" from Lasting Weight Loss. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.
The reason this review is not generic is the source wording and the canonical claim label "peptides bioglutide 14 in 13 weeks no weekly shots fyp glp1 foryoupag." In this clip, the useful excerpt is: "No more weekly shots of your GLP once?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Bioglutide is described as a quadruple agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, with a reported 13.8% weight reduction in early-stage trial data and an oral tablet formulation currently under clinical investigation. As of mid-2025, no peer-reviewed Phase 2 or Phase 3 data for bioglutide has been published in a major medical journal, meaning all efficacy figures circulating online derive from preliminary or company-disclosed sources. Patients considering GLP-1 class therapies should be evaluated and managed by a licensed medical prescriber using drugs with established FDA approval status.
- Bioglutide has no peer-reviewed Phase 2 or Phase 3 trial data published in a major journal as of mid-2025. All efficacy numbers in circulation are preliminary.
- The multi-receptor agonist concept is real science. Retatrutide, a GLP-1/GIP/glucagon tri-agonist, showed up to 24.2% weight reduction at 48 weeks in Jastreboff et al. (2023, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Bioglutide has no peer-reviewed Phase 2 or Phase 3 trial data published in a major journal as of mid-2025. All efficacy numbers in circulation are preliminary.
- The multi-receptor agonist concept is real science. Retatrutide, a GLP-1/GIP/glucagon tri-agonist, showed up to 24.2% weight reduction at 48 weeks in Jastreboff et al. (2023, NEJM).
- Oral GLP-1 delivery exists and is FDA-approved in the form of oral semaglutide (Rybelsus), so the pill format claim for bioglutide is plausible in principle, not confirmed for this specific compound.
- A Doctor of Chiropractic (DC) cannot legally prescribe GLP-1 medications in the U.S. Framing oneself as a GLP-1 expert without clarifying prescribing limitations is a credential misrepresentation risk.
- Comparing 13.8% weight loss at 13 weeks to approved drug benchmarks is misleading without matching trial length. Semaglutide's landmark STEP 1 trial ran 68 weeks (Wilding et al., 2021, NEJM).
- If someone is currently selling bioglutide as an available product, it is not an FDA-approved drug. It may be a research peptide or compounded substance with unverified purity and safety data.
- The four-receptor framework including IGF-1 for muscle preservation is speculative for this compound. IGF-1 biology is established; its application to bioglutide's clinical profile is not yet published evidence.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drjonesdc actually say?
The core pitch here is that bioglutide is a next-generation GLP-1 drug that hits four receptors, including a novel IGF-1 pathway, and delivers "13.8% weight loss" in 13 weeks, all in a daily pill with no refrigeration required. Dr. Jones frames this as the natural evolution past semaglutide (one receptor), tirzepatide (two), and retatrutide (three), with bioglutide being the "big quad." He does, to his credit, acknowledge it is still in trials.
He also positions himself as a "weight loss expert" and coach who works with a provider, and closes with an audience engagement question about what weight loss future viewers want. The video is clearly promotional in framing even if it stops short of an explicit product pitch.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lasting Weight Loss · TikTok creator
107.1K views on this video
Bioglutide: 14% ⬇️ in 13 weeks! (& NO weekly shots!) #fyp #glp1 #foryoupagе #glp1medication #glp1community
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about bioglutide has no peer-reviewed phase 2?
Bioglutide has no peer-reviewed Phase 2 or Phase 3 trial data published in a major journal as of mid-2025. All efficacy numbers in circulation are preliminary.
What does the video say about the multi-receptor agonist concept?
The multi-receptor agonist concept is real science. Retatrutide, a GLP-1/GIP/glucagon tri-agonist, showed up to 24.2% weight reduction at 48 weeks in Jastreboff et al. (2023, NEJM).
What does the video say about oral glp-1 delivery exists?
Oral GLP-1 delivery exists and is FDA-approved in the form of oral semaglutide (Rybelsus), so the pill format claim for bioglutide is plausible in principle, not confirmed for this specific compound.
What does the video say about a doctor of chiropractic (dc) cannot legally prescribe glp-1 medications?
A Doctor of Chiropractic (DC) cannot legally prescribe GLP-1 medications in the U.S. Framing oneself as a GLP-1 expert without clarifying prescribing limitations is a credential misrepresentation risk.
What does the video say about comparing 13.8% weight loss at 13 weeks to approved drug?
Comparing 13.8% weight loss at 13 weeks to approved drug benchmarks is misleading without matching trial length. Semaglutide's landmark STEP 1 trial ran 68 weeks (Wilding et al., 2021, NEJM).
What does the video say about if someone?
If someone is currently selling bioglutide as an available product, it is not an FDA-approved drug. It may be a research peptide or compounded substance with unverified purity and safety data.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lasting Weight Loss, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.